Cite
HARVARD Citation
Emons, G. et al. (2014). Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5). International journal of gynecological cancer. 24 (2), pp. 260-265. [Online].